title: Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
abstract: Signaling through the interleukin 2 receptor (IL-2R) involves phosphorylation of several proteins including Jak3, STAT5, and, in preactivated cells, STAT3. In the present study, we examined the functional status of the IL-2R-associated Jak/STAT pathway in malignant T lymphocytes from advanced skin-based lymphomas: anaplastic large T-cell lymphoma (ALCL) and Sezary syndrome (SzS). Proliferation of three ALCL cell lines (PB-1, 2A, and 2B) was partially inhibited by rapamycin, a blocker of some of the signals mediated by IL-2R, but not by cyclosporin A, FK-506, and prednisone, which suppress signals mediated by the T-cell receptor. All the cell lines expressed on their surface the high-affinity IL-2R (alpha, beta, and gamma c chains). They showed basal, constitutive phosphorylation, and coassociation of Jak3, STAT5, and STAT3. Weak basal phosphorylation of IL-2R gamma c was also detected. In regard to SzS, peripheral blood mononuclear cells from 10 of 14 patients showed basal phosphorylation of Jak3, accompanied by phosphorylation of STAT5 in 9 patients, and STAT3 in 4 patients. However, in vitro overnight culture of SzS cells without exogenous cytokines resulted in markedly decreased Jak3 and STAT5 phosphorylation, which could be reversed by stimulation with IL-2. This indicates that the basal phosphorylation of Jak3 and STAT5 in freshly isolated SzS cells is induced rather than constitutive. The basal activation of the Jak/STAT pathway involved in IL-2R signal transduction in ALCL and SzS cells reported here suggests that this pathway may play a role in the pathogenesis of cutaneous T-cell lymphomas, although the mechanism (induced versus constitutive) may vary between different lymphoma types.
authors.affiliation: Department of Pathology, University of Pennsylvania Medical Center, Philadelphia 19104, USA.
authors.forename: Q
authors.initials: Q
authors.lastname: Zhang
authors.forename: I
authors.initials: I
authors.lastname: Nowak
authors.forename: E C
authors.initials: EC
authors.lastname: Vonderheid
authors.forename: A H
authors.initials: AH
authors.lastname: Rook
authors.forename: M E
authors.initials: ME
authors.lastname: Kadin
authors.forename: P C
authors.initials: PC
authors.lastname: Nowell
authors.forename: L M
authors.initials: LM
authors.lastname: Shaw
authors.forename: M A
authors.initials: MA
authors.lastname: Wasik
mesh_terms: D002462:Cell Membrane / Q000378:metabolism; D016572:Cyclosporine / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000378:metabolism*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D053616:Janus Kinase 3; D008213:Lymphocyte Activation; D016410:Lymphoma, T-Cell, Cutaneous / Q000209:etiology / Q000378:metabolism*; D008894:Milk Proteins; D010766:Phosphorylation; D011090:Polyenes / Q000494:pharmacology; D011241:Prednisone / Q000494:pharmacology; D011485:Protein Binding; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D050796:STAT3 Transcription Factor; D050799:STAT5 Transcription Factor; D012751:Sezary Syndrome / Q000209:etiology / Q000378:metabolism; D015398:Signal Transduction; D020123:Sirolimus; D016559:Tacrolimus / Q000494:pharmacology; D015534:Trans-Activators / Q000378:metabolism*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D004268:DNA-Binding Proteins; D007166:Immunosuppressive Agents; D008894:Milk Proteins; D011090:Polyenes; D015375:Receptors, Interleukin-2; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D050799:STAT5 Transcription Factor; D015534:Trans-Activators; D016572:Cyclosporine; D011505:Protein-Tyrosine Kinases; C507933:JAK3 protein, human; D053616:Janus Kinase 3; D011241:Prednisone; D020123:Sirolimus; D016559:Tacrolimus